{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:07:42Z","timestamp":1794431262787,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T00:00:00Z","timestamp":1577232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011797","name":"Turku University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011797","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer society of South-West Finland"},{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["667403"],"award-info":[{"award-number":["667403"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jane and Aatos Erkko Foundation, Finland"},{"name":"Nordic Cancer Union, Denmark","award":["194914"],"award-info":[{"award-number":["194914"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2019.12.025","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T17:47:26Z","timestamp":1577468846000},"page":"689-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-4139","authenticated-orcid":false,"given":"Liina","family":"Salminen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimrah","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Gr\u00e8nman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Carp\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-4743","authenticated-orcid":false,"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinikka","family":"Oksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpo","family":"Lamminm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-5246","authenticated-orcid":false,"given":"Kaisa","family":"Huhtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7225","authenticated-orcid":false,"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.12.025_bb0005","unstructured":"B.F. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013., (n.d.)."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0010","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ncb3015","article-title":"The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"Mcallister","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diagnostics7010012","article-title":"Subtypes of ovarian cancer and ovarian cancer screening","volume":"7","author":"Koshiyama","year":"2017","journal-title":"Diagnostics"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0019-509X.154084","article-title":"A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer","volume":"51","author":"Zhu","year":"2014","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0045","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bjc.1984.254","article-title":"Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker","volume":"50","author":"Canney PA","year":"1984","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/475983","article-title":"Potential markers for detection and monitoring of ovarian cancer","volume":"2011","author":"Rein","year":"2011","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1 . 1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"John","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1757-2215-6-31","article-title":"Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer","volume":"6","author":"Xu","year":"2013","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0075","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.7150\/jca.21362","article-title":"The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery","volume":"8","author":"Zeng","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jso.21398","article-title":"Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis","volume":"101","author":"Kang","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/gyno.2000.5749","article-title":"The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma","volume":"77","author":"Chi","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0090","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00432-011-0977-1","article-title":"Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer","volume":"137","author":"Mury","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ijgc-00009577-200603000-00006","article-title":"The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer","volume":"16","author":"Barlow","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0100","first-page":"383","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial","volume":"110","author":"Williams","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1046\/j.1440-1746.2003.03180.x","article-title":"Elevation of serum and ascites cancer antigen 125 levels in patients with liver cirrhosis","volume":"18","author":"Xiao","year":"2003","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer","volume":"26","author":"S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0115","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: Glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0120","doi-asserted-by":"crossref","first-page":"15636","DOI":"10.3390\/ijms140815636","article-title":"Exploring the glycosylation of serum CA125","volume":"14","author":"Saldova","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0125","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.26490","article-title":"Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer","volume":"118","author":"Takeda","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0130","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/ijc.29520","article-title":"Expression of mucin 1 possessing a 3`-sulfated core1 in recurrent and metastatic breast cancer","volume":"137","author":"Ideo","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0135","doi-asserted-by":"crossref","unstructured":"K. Salminen, Liina; Nadeem, Nimrah; Rolfsen, Anne Lone; D\u00f8rum, Anne; Laajala, Teemu D; Gr\u00e8nman, Seija; Hietanen, Sakari; Heinosalo, Taija; Perheentupa, Antti; Poutanen, Matti; Bolstad, Nils; Carp\u00e9n, Olli; Lamminm\u00e4ki, Urpo; Pettersson, Kim; Gidwani, Kamlesh;, Exploratory analysis of CA125-MGL and \u2013STn glycoforms in the differential diagnostics of pelvic masses, J. Appl. Lab. Med. 3 (2020).","DOI":"10.1093\/jalm\/jfz012"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00132","article-title":"Open source infrastructure for health care data integration and machine learning analyses","author":"Isoviita","year":"2019","journal-title":"JCO Clin. Cancer Informatics"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0145","series-title":"Physiology, Pathobiology, Technology, and Clinical Applications","article-title":"Tumor markers","author":"Eleftherios","year":"2003"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0150","article-title":"A nanoparticle-Lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources","volume":"1400","author":"Gidwani","year":"2016","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.025_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1373\/jalm.2018.028266","article-title":"Europium nanoparticle-based STn monoclonal antibody recognizes epithelial ovarian cancer-associated CA125 and improves discrimination of serum CA125 from malignant and benign sources","volume":"4","author":"Gidwani","year":"2019","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0160","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2010.07.025","article-title":"CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study","volume":"119","author":"Van Altena","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0165","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.21258","article-title":"Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer","volume":"100","author":"Kang","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2011.593","article-title":"CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials\u202f: experience of the GCIG CALYPSO trial","volume":"106","author":"Alexandre","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0175","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum- resistant ovarian cancer\u202f: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.025_bb0180","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.12.025_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","article-title":"ScienceDirect Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer","volume":"78","author":"Joly","year":"2017","journal-title":"Eur. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:49:36Z","timestamp":1758772176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825819318463"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}